structural-biology-2017-posters-accepted-abstracts

5 / 23

Page 147
Notes:
conferenceseries.com
Volume 10, Issue 8 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X Structural Biology 2017
September 18-20, 2017
9th International Conference on
Structural Biology
September 18-20, 2017 Zurich, Switzerland
Targeting Trypanosoma brucei FPPs by fragment- based drug discovery
Lena Muenzker1, Joy Petrick1, Gerhard Klebe2, Andreas Marzinzik 1 and Wolfgang Jahnke 1
1Novartis Institutes for Biomedical Research, Switzerland
2Philipps University of Marburg, Germany
Trypanosoma brucei is the causative agent of Human African Trypanosomiasis (HAT), one of the most neglected diseases
with only limited medication options for treatment. Therefore, new drugs with a better safety and efficiency profile for the
two stages of the disease are highly demanded. Nitrogen-containing bisphosphonates have demonstrated anti-parasite activity.
They inhibit farnesyl pyrophosphate synthase (FPPS) and are in clinical use for bone diseases. They are also investigated for a
broader application, such as antitumor or antiparasitic agents. However, due to their pharmacokinetic properties, alternative
chemotypes are highly desired. Previous efforts at Novartis have identified an allosteric pocket on human FPPS by a fragment
based approach, and a similar pocket also exists in T. brucei FPPS. The combination of these results laid the foundation of this
work. In the first step, T. brucei FPPS protein was subjected to an NMR fragment screen using 1H, water-LOGSY and T1rho
NMR experiments. Mixtures of eight compounds were screened, and fragments fulfilling hit criteria were followed up in single
compound NMR experiments. We further validated fragment hits in protein-observed 2D-NMR experiments and estimated
Kd values by NMR. Additionally, we investigated fragment binding on T. cruzi and human FPPS to enable selectivity studies
and the comparison of results. This approach identified 25 diverse fragment hits for T. brucei FPPS, which were subjected
to crystallization experiments to identify the exact binding location and binding mode. In summary, we demonstrated the
application of a fragment-based approach for the identification of T. brucei FPPS binding compounds and further want to
drive the drug discovery process from initial fragment hits to tool compounds with high binding affinity that inhibit the FPPS
enzyme function selectively and interfere the parasitic growth.
Biography
Lena Muenzker is a Marie Curie PhD Fellow in the FragNet program under the supervision of Dr. Wolfgang Jahnke and Dr. Andreas Marzinzik in the Chemical
Biology and Therapeutics Department at Novartis Basel, Switzerland, and Prof. Gerhard Klebe at the Philipps-Universität Marburg, Germany. She graduated with a
Master's Degree in Biological Chemistry from the University of Vienna in 2015. During her studies, she did a 6-month internship on the synthesis of oligosaccharides
at Synphabase, Switzerland, and carried out her Master's Project in Prof. Paul Robert Hansen's lab at the University of Copenhagen focusing on lipidated cyclic
and bicyclic antimicrobial peptide synthesis. After her studies, she took the opportunity to join Prof. Nathanael Gray's lab at the Dana Farber Cancer Institute and
learned new methods related to protein kinase inhibitors. She will expand her experience in her PhD project, which comprises structural biophysics and FBDD to
identify novel inhibitors of Trypanosoma brucei FPPS.
Lena Muenzker et al., J Proteomics Bioinform 2017, 10:8(Suppl)
DOI: 10.4172/0974-276X-C1-0101
Figure1: T. brucei FPPS complexed with
bisphosphonate (PDB: 2i19)